Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced that it has issued and sold an ...
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced that it has issued and sold an ...
Gainers: [[ADMS]] +13.2%. [[CTMX]] +5.6%. [[MSTR]] +4.9%. [[FARM]] +4.8%. [[NERV]] +4%.Losers: [[CATB]] -10.6%. [[PTVE]] -8%. [[MRVI]] -3.9%. [[ZI]] -3.8%. [[ICON]] -3.5%. For further details see: MSTR, ZI, ADMS and CATB among after-hours movers
Steve Cohen’s Point72 Asset Management reports a 9.1% in CytomX Therapeutics (CTMX), representing 5.52M shares.Shares up 8.7% after-hours.CytomX Therapeutics secures $100M capital raise For further details see: CytomX Therapeutics surges after Steve Cohen's Point72 disc...
Gainers: Vinco Ventures (BBIG) +312%.ADiTx Therapeutics (ADTX) +90%.Qutoutiao (QTT) +65%.Ideal Power (IPWR) +51%.BiondVax Pharmaceuticals (BVXV) +39%.Celsion (CLSN) +34%.Polar Power (POLA) +33%.Addex Therapeutics (ADXN) +28%.Pioneer Power Solutions (PPSI) +27%.Barnwell Industri...
Shares of several biotechs were falling today for the same underlying reason. Editas Medicine (NASDAQ: EDIT) stock was down 10% as of 11:07 a.m. EST on Thursday. Shares of Inovio Pharmaceuticals (NASDAQ: INO) were 6.4% lower. Dyne Therapeutics (NASDAQ: DYN) stock was...
Gainers: ADiTx Therapeutics (ADTX) +63%, Celsion (CLSN) +58%, Genetic Technologies (GENE) +39%, Addex Therapeutics (ADXN) +26%, ThermoGenesis Holdings (THMO) +19%.Losers: Obalon Therapeutics (OBLN) -25%, Cancer Genetics (CGIX) -24%, ...
Cancer Genetics (CGIX) -18%.Obalon Therapeutics (OBLN) -17%.Adamis Pharmaceuticals (ADMP) -17%.Marathon Patent Group (MARA) -11% as Bitcoin crumbles despite good news rolls in.Riot Blockchain (RIOT) -11% as Bitcoin crumbles despite good news rolls in.Foresight Autonomous (...
CytomX Therapeutics (CTMX) has priced its public offering of ~14.3M common shares at $7.00/share, for gross proceeds of $100M.Underwriters' over-allotment is an additional ~2.1M shares. Net proceeds will be used to further develop its proprietary Probody therapeutics pipeline and re...
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced the pricing of an underwritten ...
News, Short Squeeze, Breakout and More Instantly...
CytomX Therapeutics Inc. Company Name:
CTMX Stock Symbol:
NASDAQ Market:
CytomX Therapeutics Inc. Website:
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a firesid...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. “Chris has mad...